{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:11:51Z","timestamp":1768623111015,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.ygyno.2008.05.036","type":"journal-article","created":{"date-parts":[[2008,7,25]],"date-time":"2008-07-25T08:34:20Z","timestamp":1216974860000},"page":"S1-S10","source":"Crossref","is-referenced-by-count":83,"special_numbering":"S1","title":["Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: Improving upon nature"],"prefix":"10.1016","volume":"110","author":[{"given":"Tino F.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oberdan","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2008.05.036_bib1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","article-title":"The epidemiology of human papillomavirus infections","volume":"32","author":"Baseman","year":"2005","journal-title":"J Clin Virol"},{"issue":"7364","key":"10.1016\/j.ygyno.2008.05.036_bib2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.325.7364.572","article-title":"Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study","volume":"325","author":"Kjaer","year":"2002","journal-title":"Br Med J"},{"issue":"24","key":"10.1016\/j.ygyno.2008.05.036_bib3","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1001\/jama.286.24.3106","article-title":"Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia","volume":"286","author":"Schlecht","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ygyno.2008.05.036_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"22","key":"10.1016\/j.ygyno.2008.05.036_bib5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199911253412201","article-title":"Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer","volume":"341","author":"Wallin","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ygyno.2008.05.036_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.ygyno.2008.05.036_bib7","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2: the burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2008.05.036_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality","volume":"31","author":"Bosch","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"5","key":"10.1016\/j.ygyno.2008.05.036_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"10.1016\/j.ygyno.2008.05.036_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ygyno.2008.05.036_bib11","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.ygyno.2008.05.036_bib12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/jcp.2004.022863","article-title":"Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study","volume":"58","author":"Cuschieri","year":"2005","journal-title":"J Clin Pathol"},{"issue":"18","key":"10.1016\/j.ygyno.2008.05.036_bib13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/87.18.1365","article-title":"Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia","volume":"87","author":"Ho","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.05.036_bib14","series-title":"24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3\u20139","article-title":"Risk of cervical lesions following incident human papillomavirus infection in young women without evidence of prior exposure","author":"Trottier","year":"2007"},{"issue":"9","key":"10.1016\/j.ygyno.2008.05.036_bib15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/89.9.630","article-title":"Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia","volume":"89","author":"de Gruijl","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 3","key":"10.1016\/j.ygyno.2008.05.036_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.vaccine.2006.05.115","article-title":"Chapter 1: HPV in the etiology of human cancer","volume":"24","author":"Mu\u00f1oz","year":"2006","journal-title":"Vaccine"},{"issue":"Pt 6","key":"10.1016\/j.ygyno.2008.05.036_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1042\/BST0351456","article-title":"HPV: from infection to cancer","volume":"35","author":"Stanley","year":"2007","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"10.1016\/j.ygyno.2008.05.036_bib18","first-page":"174","article-title":"In situ hybridization analysis of HPV 16 DNA sequences in early cervical neoplasia","volume":"123","author":"Crum","year":"1986","journal-title":"Am J Pathol"},{"issue":"24","key":"10.1016\/j.ygyno.2008.05.036_bib19","doi-asserted-by":"crossref","first-page":"11217","DOI":"10.1073\/pnas.88.24.11217","article-title":"Human papillomavirus 16 E7 protein is associated with the nuclear matrix","volume":"88","author":"Greenfield","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ygyno.2008.05.036_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0046-8177(92)90232-R","article-title":"Human papillomavirus type 16 and 18 gene expression in cervical neoplasias","volume":"23","author":"Stoler","year":"1992","journal-title":"Hum Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2008.05.036_bib21","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ygyno.2008.05.036_bib22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2567.2006.02465.x","article-title":"Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia","volume":"119","author":"Passmore","year":"2006","journal-title":"Immunology"},{"issue":"Pt 2","key":"10.1016\/j.ygyno.2008.05.036_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/0022-1317-80-2-409","article-title":"Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16","volume":"80","author":"Bontkes","year":"1999","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1016\/j.ygyno.2008.05.036_bib24","first-page":"1700","article-title":"Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study","volume":"58","author":"de Gruijl","year":"1998","journal-title":"Cancer Res"},{"issue":"29","key":"10.1016\/j.ygyno.2008.05.036_bib25","doi-asserted-by":"crossref","first-page":"12087","DOI":"10.1073\/pnas.0704672104","article-title":"Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens","volume":"104","author":"van der Burg","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ygyno.2008.05.036_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/088282403322017893","article-title":"Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology","volume":"16","author":"Rocha-Zavaleta","year":"2003","journal-title":"Viral Immunol"},{"issue":"9","key":"10.1016\/j.ygyno.2008.05.036_bib27","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jmv.20901","article-title":"Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia","volume":"79","author":"Passmore","year":"2007","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.ygyno.2008.05.036_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","article-title":"Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica","volume":"13","author":"Viscidi","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.ygyno.2008.05.036_bib29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/JVI.70.2.960-965.1996","article-title":"Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus","volume":"70","author":"Christensen","year":"1996","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.ygyno.2008.05.036_bib30","doi-asserted-by":"crossref","first-page":"8784","DOI":"10.1128\/JVI.00552-07","article-title":"Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition","volume":"81","author":"Day","year":"2007","journal-title":"J Virol"},{"issue":"25","key":"10.1016\/j.ygyno.2008.05.036_bib31","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2008.05.036_bib32","series-title":"Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals","year":"2007"},{"issue":"6","key":"10.1016\/j.ygyno.2008.05.036_bib33","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/JVI.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.ygyno.2008.05.036_bib34","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1128\/JVI.71.11.8109-8115.1997","article-title":"Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2","volume":"71","author":"Parr","year":"1997","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.ygyno.2008.05.036_bib35","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ygyno.2008.05.036_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrmicro867","article-title":"Delivering on the promise: HPV vaccines and cervical cancer","volume":"2","author":"Schiller","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.ygyno.2008.05.036_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/CVI.00118-07","article-title":"Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies","volume":"15","author":"Kemp","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"26","key":"10.1016\/j.ygyno.2008.05.036_bib38","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"33\u201334","key":"10.1016\/j.ygyno.2008.05.036_bib39","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.ygyno.2008.05.036_bib40","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.vaccine.2006.05.119","article-title":"Chapter 11: HPV vaccines: commercial research & development","volume":"24","author":"Inglis","year":"2006","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.ygyno.2008.05.036_bib41","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.vaccine.2006.05.110","article-title":"Chapter 12: prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"5601","key":"10.1016\/j.ygyno.2008.05.036_bib42","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory B cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"issue":"Suppl 2","key":"10.1016\/j.ygyno.2008.05.036_bib43","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0264-410X(03)00198-1","article-title":"Antigen dependent and independent mechanisms that sustain serum antibody levels","volume":"21","author":"Traggiai","year":"2003","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.ygyno.2008.05.036_bib44","first-page":"877","article-title":"Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory","volume":"19","author":"Banatvala","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2008.05.036_bib45","series-title":"Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer, Tampa, FL, USA, Mar 9\u201312","article-title":"Sustained immunogenicity and high efficacy against HPV-16\/18 related cervical neoplasia: long-term follow-up with Cervarix\u2122 (GSKs HPV 16\/18 AS04 candidate vaccine)","author":"Harper","year":"2008"},{"issue":"9447","key":"10.1016\/j.ygyno.2008.05.036_bib46","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518","key":"10.1016\/j.ygyno.2008.05.036_bib47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5\u00a0years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2008.05.036_bib48","series-title":"European Society for Paediatric Infectious Disease, Graz, Austria, May 14\u201316","article-title":"High and sustained HPV-16 and 18 antibody levels through 6.4\u00a0years in women vaccinated with Cervarix\u2122 (GSK HPV-16\/18 AS04 vaccine)","author":"Wheeler","year":"2008"},{"issue":"21","key":"10.1016\/j.ygyno.2008.05.036_bib49","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ygyno.2008.05.036_bib50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"9580","key":"10.1016\/j.ygyno.2008.05.036_bib51","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ygyno.2008.05.036_bib52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"issue":"5","key":"10.1016\/j.ygyno.2008.05.036_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ygyno.2008.05.036_bib54","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5\u00a0years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.ygyno.2008.05.036_bib55","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0264-410X(99)00566-6","article-title":"A hepatitis B vaccine formulated with a novel adjuvant system","volume":"18","author":"Ambrosch","year":"2000","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ygyno.2008.05.036_bib56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"21","key":"10.1016\/j.ygyno.2008.05.036_bib57","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ygyno.2008.05.036_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1586\/14760584.4.5.615","article-title":"Glycoprotein D adjuvant herpes simplex virus vaccine","volume":"4","author":"Bernstein","year":"2005","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.ygyno.2008.05.036_bib59","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.vaccine.2004.06.006","article-title":"Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04","volume":"23","author":"Boland","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ygyno.2008.05.036_bib60","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Gar\u00e7on","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ygyno.2008.05.036_bib61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-1-4615-1823-5_21","article-title":"Monophosphoryl lipid A as an adjuvant. Past experiences and new directions","volume":"6","author":"Ulrich","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.ygyno.2008.05.036_bib62","series-title":"24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3\u20139","article-title":"Evaluation of HPV neutralizing antibodies from an extended follow up study through 5.5\u00a0years in women vaccinated with GSK's prophylactic cervical cancer candidate vaccine","author":"Dessy","year":"2007"},{"key":"10.1016\/j.ygyno.2008.05.036_bib63","series-title":"American Association for Cancer Research Annual Meeting, Los Angeles, CA, USA, Apr 14\u201318","article-title":"Substantial impact on precancerous lesions and HPV infections through 5.5\u00a0years in women vaccinated with the HPV-16\/18 L1 VLP AS04 candidate vaccine","author":"Gall","year":"2007"},{"key":"10.1016\/j.ygyno.2008.05.036_bib64","series-title":"24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3\u20139","article-title":"Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by Cervarix\u2122: modelling of sustained antibody responses","author":"David","year":"2007"},{"issue":"24","key":"10.1016\/j.ygyno.2008.05.036_bib65","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1128\/JVI.01583-06","article-title":"Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV\/cottontail rabbit papillomavirus chimeric papillomavirus particles","volume":"80","author":"Mejia","year":"2006","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ygyno.2008.05.036_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18","volume":"321","author":"Pastrana","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.ygyno.2008.05.036_bib67","series-title":"24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, Nov 3\u20139","article-title":"Induction of cervical mucosal HPV IgG in women 15\u201355\u00a0years old following systemic vaccination with GSK's prophylactic cervical cancer candidate vaccine","author":"Poncelet","year":"2007"},{"key":"10.1016\/j.ygyno.2008.05.036_bib68","series-title":"25th Annual Meeting of the European Society for Paediatric Infectious Diseases, Porto, Portugal, May 2\u20134","article-title":"Long-term safety and immunogenicity of a cervical cancer candidate vaccine in 10- to 14-year-old adolescent girls","author":"Rombo","year":"2007"},{"key":"10.1016\/j.ygyno.2008.05.036_bib69","series-title":"15th International Meeting of the European Society of Gynaecological Oncology (ESGO), Berlin, Germany, Oct 28\u2013Nov 1","article-title":"Sustained HPV-16 and 18 antibody levels through 5.5\u00a0years in women vaccinated with the HPV-16\/18 L1 VLP AS04 candidate vaccine","author":"Harper","year":"2007"},{"issue":"5","key":"10.1016\/j.ygyno.2008.05.036_bib70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ijc.10735","article-title":"Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women","volume":"102","author":"Bory","year":"2002","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2008.05.036_bib71","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.11222","article-title":"Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study","volume":"106","author":"Dalstein","year":"2003","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2008.05.036_bib72","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/315086","article-title":"Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer","volume":"180","author":"Franco","year":"1999","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.ygyno.2008.05.036_bib73","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1086\/428779","article-title":"A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica","volume":"191","author":"Castle","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ygyno.2008.05.036_bib74","series-title":"American Society of Clinical Oncology Annual Meeting, Chicago, USA, Jun 1\u20135","article-title":"Human papillomavirus (HPV) 16\/18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18\u00a0months after vaccination in women up to age 55\u00a0years","author":"Schwarz","year":"2007"},{"issue":"35","key":"10.1016\/j.ygyno.2008.05.036_bib75","first-page":"175","article-title":"The impact of preventive HPV vaccination","volume":"6","author":"Roden","year":"2006","journal-title":"Discov Med"},{"issue":"7","key":"10.1016\/j.ygyno.2008.05.036_bib76","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808004939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808004939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T07:39:21Z","timestamp":1588837161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808004939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0090825808004939"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.05.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}